LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.

被引：0
|
作者：
Lee, Hans C.
Bumma, Naresh
Richter, Joshua Ryan
Dhodapkar, Madhav V.
Hoffman, James E.
Suvannasankha, Attaya
Zonder, Jeffrey A.
Shah, Mansi R.
Lentzsch, Suzanne
Maly, Joseph J.
Ye, Jing Christine
Wu, Ka Lung
DeVeaux, Michelle
Chokshi, Dhruti
Boyapati, Anita
Hazra, Anasuya
Rodriguez-Lorenc, Karen
Kroog, Glenn Scott
Houvras, Yariv J.
Jagannath, Sundar
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Emory Univ, Sch Med, Atlanta, GA USA
[5] Univ Miami Hlth Syst, Miami, FL USA
[6] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA
[7] Roudebush VAMC, Indianapolis, IN USA
[8] Karmanos Canc Inst, Detroit, MI USA
[9] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[10] Columbia Univ, Med Ctr, New York, NY USA
[11] Norton Canc Inst, Louisville, KY USA
[12] Univ Michigan, Ann Arbor, MI USA
[13] Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
[14] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8006
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)
    Berenson, James R.
    To, Jennifer
    Spektor, Tanya M.
    Martinez, Daisy
    Sanchez, Armando J.
    Turner, Carley
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura V.
    Moss, Robert A.
    Nassir, Youram
    Patel, Ravindranath
    Bessudo, Alberto
    Greenwald, Daniel
    Boccia, Ralph V.
    Lim, Stephen
    Vescio, Robert
    BLOOD, 2019, 134
  • [32] Osteoblastic activation and response to VELCADE® in patients with relapsed/refractory multiple myeloma (MM).
    Zangari, M
    Lee, CK
    Barlogie, B
    Najarian, K
    Kang, SH
    Yaccoby, S
    Esseltine, D
    Stover, JM
    Tricot, GJ
    BLOOD, 2004, 104 (11) : 309B - 309B
  • [33] Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.
    Chanan-Khan, Asher Alban
    Gharibo, Mecide
    Jagannath, Sundar
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    DePaolo, Dawn
    Lee, Kelvin P.
    Miller, Kena
    Guild, Robin
    Zildjian, Sybil
    Qin, Albert
    BLOOD, 2008, 112 (11) : 1263 - 1264
  • [34] A phase 1 trial of lenalidomide (REVLIMID®) with bortezomib (VELCADE®) in relapsed and refractory multiple myeloma.
    Richardson, P
    Schlossman, R
    Munshi, N
    Avigan, D
    Jagannath, S
    Alsina, M
    Doss, D
    McKenney, M
    Hande, K
    Farrell, M
    Gorelik, S
    Colson, K
    Warren, D
    Lunde, L
    Michelle, R
    Cole, G
    Mitsiades, C
    Hideshima, T
    Myers, T
    Knight, R
    Anderson, K
    BLOOD, 2005, 106 (11) : 110A - 111A
  • [35] A phase 1, multi-center, dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma (MM).
    Wang, M
    Talpaz, M
    Jagannath, S
    Chanan-Khan, AA
    Alexanian, R
    Weber, DM
    Gavino, M
    Estrov, Z
    Harris, PJ
    Picker, D
    Schlossman, RL
    Tassone, P
    Anderson, KC
    Munshi, NC
    BLOOD, 2005, 106 (11) : 36A - 37A
  • [36] A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.
    Gasparetto, Cristina
    Green, Michael
    Srinivasan, Anandgopal
    Kang, Yubin
    Rizzieri, David A.
    Decastro, Carlos
    Diehl, Louis F.
    Beaven, Anne
    Li, Zighuo
    Rao, Arati V.
    Garrett, Anderson
    Tuchman, Sascha
    Long, Gwynn D.
    BLOOD, 2015, 126 (23)
  • [37] TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma
    Abu-Rashed, Esraa
    Sharif, Joseph
    Rocci, Alberto
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S363 - S365
  • [38] A Phase 3 Study of Carfilzomib and Dexamethasone (Kd) in Patients With Relapsed and Refractory Multiple Myeloma (MM) in China
    Du, Juan
    Fang, Baijun
    Li, Jian
    Jin, Jie
    Wang, Shunqing
    Zou, Dehui
    Cai, Zhen
    Wang, Hongxiang
    Hu, Jianda
    Li, Wei
    Fu, Chengcheng
    Shao, Zonghong
    Xia, Zhongjun
    Liu, Peng
    Niu, Ting
    Tang, En-Tzu
    Kimball, Amy
    Hou, Jian
    Chen, Wenming
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E267 - E268
  • [39] Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma.
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeanenne Joy
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma.
    Di Raimondo, F
    Pennisi, A
    Buglio, D
    Fiumara, P
    Palumbo, GA
    Giustolisi, R
    BLOOD, 2003, 102 (11) : 385B - 385B
12345